HLA genotype as a marker of multiple sclerosis prognosis: A pilot study

The identification of a biomarker with prognostic value is an unmet need in multiple sclerosis (MS). The objective of this study was to investigate a possible association of HLA genotype with disease status and progression in MS, based on comprehensive and sensitive clinical and magnetic resonance i...

Full description

Saved in:
Bibliographic Details
Published in:Journal of the neurological sciences 2017-04, Vol.375, p.348-354
Main Authors: Lysandropoulos, Andreas P., Mavroudakis, Nicolas, Pandolfo, Massimo, El Hafsi, Kaoutar, van Hecke, Wim, Maertens, Anke, Billiet, Thibo, Ribbens, Annemie
Format: Article
Language:English
Subjects:
Adult
Aged
Clinical score
Disability Evaluation
Disease Progression
Female
Gene Frequency
Genetic Predisposition to Disease - genetics
Genotype
HLA genotype
HLA-B Antigens - genetics
Humans
Longitudinal Studies
Magnetic Resonance Imaging
Male
Middle Aged
Multiple sclerosis
Multiple Sclerosis - diagnostic imaging
Multiple Sclerosis - genetics
Pilot Projects
Prognostic
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The identification of a biomarker with prognostic value is an unmet need in multiple sclerosis (MS). The objective of this study was to investigate a possible association of HLA genotype with disease status and progression in MS, based on comprehensive and sensitive clinical and magnetic resonance imaging (MRI) parameters to measure disease effects. A total of 118 MS patients (79 females, 39 males) underwent HLA typing. Patient MS status was assessed at two time points in a 2-year interval, based on clinical scores (including EDSS, MSSS, T25FW, 9-HPT, SDMT, BVMT, CVLT-II) and MRI evaluations. Quantitative brain MRI values were obtained for whole brain atrophy, FLAIR lesion volume change and number of new lesions using MSmetrix. Predefined HLA patient groups were compared as of disease status and progression. Global assessment was achieved by an overall t-statistic and assessment per measurement by a Welch test and/or Mann Whitney U test. The effects of multiple covariates, including age, gender and disease duration as well as scan parameters, were also evaluated using a regression analysis. The HLA-A*02 allele was associated with better outcomes in terms of MSSS, EDSS and new lesion count (Welch test p-value
ISSN:0022-510X
1878-5883
DOI:10.1016/j.jns.2017.02.019